PPA1 Regulates Systemic Insulin Sensitivity by Maintaining Adipocyte Mitochondria Function as a Novel PPARγ Target...

Area of Science:

• Metabolic disorders
• Adipose tissue biology
• Mitochondrial function

Background:

• Obesity-associated metabolic disorders are linked to impaired mitochondrial function in adipose tissue.
• Inorganic pyrophosphatase 1 (PPA1), an enzyme in cellular anabolism, has an unexamined role in metabolic syndromes.
• PPA1 hydrolyzes inorganic pyrophosphate, a process vital for cellular growth and function.

Purpose of the Study:

• To investigate the role of Inorganic pyrophosphatase 1 (PPA1) in metabolic homeostasis and adipose tissue function.
• To determine the impact of PPA1 deficiency on glucose tolerance, insulin resistance, and adipose tissue development.
• To elucidate the molecular mechanisms by which PPA1 influences mitochondrial function in adipocytes.

Main Methods:

• Generation and analysis of global PPA1 knockout mice (PPA1+/-) fed a high-fat diet.
• In vivo studies involving adeno-associated virus-mediated overexpression of PPA1 in adipose tissue.
• Mechanistic investigations using cell-specific knockdown of PPA1 in Drosophila melanogaster fat body.
• Assessment of glucose tolerance, insulin resistance, adipose tissue morphology, lipid accumulation, and mitochondrial function.

Main Results:

• PPA1 knockout mice exhibited impaired glucose tolerance and severe insulin resistance under high-fat diet conditions.
• Loss of PPA1 led to defective adipose tissue development and ectopic lipid accumulation.
• Overexpression of PPA1 in adipose tissue partially reversed metabolic dysfunction in knockout mice.
• PPA1 was identified as a PPARγ target gene essential for maintaining adipocyte mitochondrial function.
• Knockdown of PPA1 in Drosophila fat body resulted in mitochondrial abnormalities, reduced lipid storage, and increased starvation sensitivity.

Conclusions:

• PPA1 plays a critical role in maintaining adipose tissue function and overall metabolic homeostasis.
• Dysregulation of PPA1 contributes to the development of obesity-associated metabolic disorders.
• Targeting PPA1 may offer a therapeutic strategy for metabolic diseases.